LUNGevity Announces $1.2M in Lung Cancer Workforce Development Research Awards

LUNGevity Foundation is proud to announce the recipients of four awards to bolster the lung cancer research workforce— the Career Development Award, the VA Research Scholar Award, the Health Equity and Inclusiveness Research Fellow Award, and the ASTRO-LUNGevity Residents/Fellows in Radiation Oncology Seed Grant.

Tags

What Is a Clinical Trial

Lung cancer clinical trials are carefully designed research studies to evaluate and learn more about new drugs and treatments. They give people the ability to participate in lung cancer research and access to new treatments that otherwise may not be available to them, all under the close supervision of medical experts. 

Watch Recorded Expert Sessions From ILCSC

The International Lung Cancer Survivorship Conference (ILCSC) is a free virtual educational conference for people with lung cancer, caregivers, and advocates. The 2023 conference was held September 22-23.  

The recorded sessions from this conference are available to registered participants through December 21, 2023, at www.lungevity.org/ilcsc. If you did not register for the conference but would like to view the recordings, you may still register for free access. The recordings are available until December 21.

The Latest Lung Cancer Science: Highlights of WCLC 2023

I had the privilege of attending the 2023 World Conference on Lung Cancer (WCLC) in Singapore with my colleague Dr. Bellinda King-Kallimanis. WCLC, the world's largest meeting dedicated to lung cancer and other thoracic malignancies, is an excellent forum for learning about the latest research into the early detection and treatment of lung cancer. Apart from the science, it was inspiring to see fellow advocates and network with brilliant researchers, all razor-focused on improving the outcomes and lives of people diagnosed with lung cancer.

Tags

Decentralized Trials: Bringing Clinical Trials Closer to the Patient

While participating in clinical trials can provide substantial benefits to people with lung cancer, the resources required to do so may pose significant hurdles, especially to those who don’t live close to where trials are held, such as academic medical centers or major oncology network sites. Decentralized clinical trials remove some hurdles to trial participation for patients and are thus important for improving trial access for larger and more diverse groups of people. The U.S.

We have succeeded in targeting KRAS G12C mutations. Now what?

We currently have two FDA-approved drugs, sotorasib and adagrasib, that are used to treat advanced-stage NSCLC with KRAS G12C mutations. Watch the discussion with guest speakers Rosemary Conway (patient advocate who was diagnosed with KRAS G12D-positive NSCLC) and Dr. Kathryn Arbour, MD (thoracic oncologist, assistant attending physician at Memorial Sloan Kettering Cancer Center). Dr. Arbour received a 2020 LUNGevity Career Development Award and is studying how lung cancer cells become resistant to KRAS G12C-blocking drugs.

2023 ASCO: Highlights of Lung Cancer Research

Recently, members of LUNGevity Foundation joined thousands of attendees from the US and around the world, including oncologists, scientists, biotech and pharmaceutical representatives, advocates, and patients, to discuss lifesaving cancer research at the annual meeting of the American Society of Clinical Oncology (ASCO) in Chicago from June 2 through June 6, 2023.

Tags

Tracing the Clues of a Global Killer: How Dr. Charles Swanton’s Research Is Shedding New Light on Lung Cancer

As Chief Investigator of the groundbreaking Cancer Research UK (CRUK) TRACERx study, you could say that Dr. Charles Swanton is having a moment. Launched nine years ago, TRACERx seeks to understand lung cancer at its most basic level, “tracing” the clues that may predict how it starts and eventually changes over time so that doctors can treat it better.

Tags

Tackling the Biggest Challenges in Cancer

Cancer Grand Challenges is a partnership between Cancer Research UK (CRUK) and the National Cancer Institute (NCI), which funds global teams of leading researchers across various scientific disciplines to tackle some of the toughest challenges in cancer research. As Dinah Singer, Acting Director of NCI’s Center for Strategic Scientific Initiatives says, “Cancer research is a global endeavor.” 

Real-World Drug Development at the Targeted Therapies of Lung Cancer Meeting

The development of new treatments for any disease relies on the collaborative efforts of many different stakeholders, such as scientists, clinicians, patient advocacy groups, regulators, and pharmaceutical and biotech companies.

During scientific conferences that happen throughout the year, stakeholders cobble together opportunities to discuss the current state of treatments and strategize ways to bring emerging lifesaving treatments to patients.